Related Experiment Videos
Serologic detection of diffuse large B-cell lymphoma-associated antigens
Amanda P Liggins1, Barbara A Guinn, Chris S Hatton
1Nuffield Department of Clinical Laboratory Sciences, University of Oxford, LRF Immunodiagnostics Unit, John Radcliffe Hospital, Oxford, United Kingdom.
International Journal of Cancer
|May 4, 2004
Summary
Researchers identified new antigens linked to diffuse large B-cell lymphoma (DLBCL) using SEREX. These antigens show potential as diagnostic markers and targets for immunotherapy in DLBCL patients.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is a common non-Hodgkin's lymphoma with poorly understood genetic drivers.
- Cancer-testis antigens (CTAs) identified via SEREX are promising targets for cancer immunotherapy.
- Identifying novel DLBCL-specific antigens is crucial for advancing diagnostics and therapeutics.
Purpose of the Study:
- To identify novel antigens associated with DLBCL using the SEREX technique.
- To evaluate the reactivity of identified antigens against DLBCL patient sera.
- To confirm the expression of identified antigens in DLBCL cell lines.
Main Methods:
- Serological analysis of recombinant cDNA expression libraries (SEREX) screening of a testis library with DLBCL patient serum.
- Identification and characterization of 28 distinct antigens from positive clones.
- Cross-reactivity screening of identified antigens with sera from DLBCL, leukemia patients, and healthy donors.
- Reverse-transcriptase PCR (RT-PCR) to confirm mRNA expression in DLBCL cell lines.
Main Results:
- SEREX identified 28 distinct antigens, including 2 novel and 8 uncharacterized ones.
- Seven antigens were specifically recognized by DLBCL sera but not by healthy donor sera.
- Two of these antigens also showed reactivity with leukemia patient sera.
- mRNA expression of most identified antigens was confirmed in DLBCL cell lines.
Conclusions:
- The study identified several DLBCL-associated antigens with potential diagnostic and prognostic value.
- These antigens may serve as targets for developing novel immunotherapies for DLBCL and other hematologic malignancies.